FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Expires: December 31, 2014 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person * Warbington Timothy (Last) (First) (Middle) 211 E. OSBORN ROAD (Street) PHOENIX AZ 85012 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. [ CELZ ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner X Officer (give title below) Other (specify below) President & CEO
	3. Date of Earliest Transaction (Month/Day/Year) 09/24-05:00/2026
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24-05:00/2026		A		1,000,000	A	(1)	1,034,904 (2)	I (2)	By entity (2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of common stock were issued to Creative Acquisition Corp. ("CAC") pursuant to a Stock Purchase Agreement dated September 24, 2026 (the "SPA"), between CAC and the Issuer, pursuant to which the Issuer purchased 4,000,000 shares of common stock of BioDefense, Inc. ("BioDefense") from CAC for a purchase price consisting of $200,000 in cash and 1,000,000 shares of the Issuer's common stock. After giving effect to the transactions under the SPA, the Issuer owns 80% (16,000,000) of the outstanding shares of BioDefense and CAC owns 20% (4,000,000) of the outstanding shares of BioDefense. Timothy Warbington is the Chairman and Chief Executive Officer of CAC, indirectly owns all of its outstanding shares of capital stock, and beneficially owns the shares held by CAC.

2. Amount of shares of the Issuer's common stock beneficially owned following the reported transaction consists of 12,209 shares owned by Timothy Warbington, 1,000,000 shares owned by CAC, and 22,695 shares owned by Creative Medical Health, Inc. ("CMH"). Mr. Warbington is the President of CMH, owns substantially all of its outstanding shares of common stock and beneficially owns the shares held by CMH.

	/s/ Timothy Warbington	09/25/2026
	** Signature of Reporting Person	Date
	/s/ Timothy Warbington, Chairman and CEO of Creative Acquisition Corp.	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.